FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 698 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Generic Sunitinib December 18, 2020 Droplet Transmission vs. Airborne… What’s the difference? August 10, 2020 FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,... April 8, 2026 Efficacy, Safety, and Translational Data from Durvalumab Plus Ceralasertib in Advanced/Metastatic... February 19, 2024 Load more HOT NEWS After 5 Years of Follow-Up, the Median PFS Has Yet To... ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research,... Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer ΣΤΑΤΙΣΤΙΚΑ
